CRL · Charles River Laboratories International, Inc.

Charles River Laboratories International Inc CRL

Provides drug discovery, non-clinical safety testing, and research model services to pharmaceutical and biotechnology companies.

Daily briefSeptember 24, 2026

Charles River jumps after unveiling 'Pathway to Purpose' strategy

+6.17% to $294.44 from $277.33

CEO Birgit Girshick presented a refreshed strategic vision called “Pathway to Purpose,” aimed at modernizing the company and expanding AI-assisted digital tools to shorten drug-development timelines.
The company’s “Create the Future” program targets more than $300 million in cumulative savings from 2027 through 2030 through automation and process simplification.
Charles River reaffirmed 2026 guidance, with revenue and non-GAAP earnings per share expected at the upper end of prior ranges, and issued new long-term financial targets through 2030.

Sources: BioSpace · StockTitan

Daily briefAugust 5, 2026

+11.36% to $260.72 from $234.12

Q2 revenue of $1.00 billion beat the $979.9 million estimate; adjusted EPS of $3.02 beat the $2.73 estimate.
The company raised FY2026 adjusted EPS guidance to $11.15-$11.45, from a prior $10.80-$11.30.
FY2026 revenue forecast was raised to $3.879 billion-$3.920 billion, from a prior $3.794 billion-$3.854 billion.
The Discovery and Safety Assessment segment booked its highest net book-to-bill ratio in nearly four years, with demand improving across large pharma and small-cap biotech clients.

Sources: StockStory · Benzinga